Annovis Bio, Inc. (ANVS) shares surged 37.18 percent to $3.21, rising $0.87 on Monday's trading after the company reported new clinical data highlighting the role of amyloid co-pathology in Parkinson's disease and the positive impact of its drug candidate, buntanetap. ANVS is currently trading at $3.21 after opening at $2.37, compared with a previous close of $2.34 on the Nasdaq. Shares have moved between $2.3559 and $4.00 so far today, with trading volume soaring to 36,140,224 versus an average of 627,225. Over the past 52 weeks, the stock has ranged between $1.11 and $7.52.
The company said its Phase 3 trial in early Parkinson's showed that buntanetap halted cognitive decline across the overall patient population, with the strongest improvements seen in patients with mild dementia.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.